Ocugen (OCGN) Reports Q1 EPS

Ocugen, Inc. (NASDAQ:OCGN) is one of the 10 Best Penny Stocks to Buy Before They Explode.

On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment in two late-stage programs during the first few months of 2026 and is continuing preparations toward initiating its first BLA submission for retinitis pigmentosa and a registration trial for dry AMD later this year. Musunuri also said Ocugen believes it is executing efficiently against its strategic plans, citing productivity levels, recent financing activity, and milestone progress aimed at supporting long-term value creation.

A day earlier, Ocugen, Inc. (NASDAQ:OCGN) announced plans to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers under Rule 144A of the Securities Act.

Ocugen (OCGN) Reports Q1 EPS

Pressmaster/Shutterstock.com

Last month, Ocugen, Inc. (NASDAQ:OCGN) announced that dosing was completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial evaluating OCU410ST for Stargardt disease. The company said the trial represents its second late-stage clinical program and added that it plans to submit a BLA for OCU410ST by mid-2027 as part of its broader goal of filing three BLAs by 2028.

Ocugen, Inc. (NASDAQ:OCGN) is a biopharmaceutical company focused on developing and commercializing gene therapies, cell therapies, biologics, and vaccines.

While we acknowledge the risk and potential of OCGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OCGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.